About Magnendo
Magnendo is a Healthcare company based in Boston (United States) founded in 2024 by Miki Rosenberg and Yoonho Kim. Magnetically steerable guidewires for neurovascular disease treatments are developed. Magnendo has raised $20.25 million across 2 funding rounds. Its chief executive, as recorded, is Yoonho Kim. Magnendo offers products and services including Robotic Guidewire and Neurovascular Robotic System. Its focus areas include Life Sciences, Neurology, Medical Devices and Therapeutic Devices. Its legal entity is Magnendo Corp. Its competitors include Route 92 Medical and Autonomix; 2 of its 2 listed competitors have raised funding.
Company details
Magnendo was founded in 2024 in Boston, United States, within the medtech sector focused on neurovascular applications. Devices such as magnetically steerable soft-robotic guidewires are developed for minimally invasive procedures addressing stroke and brain aneurysms. Operations center on improving procedural efficiency and reducing complications in the brains vasculature, with services targeted at healthcare providers to enhance patient outcomes.
- Headquarters Boston, United States
- Founders Miki Rosenberg, Yoonho Kim
- SectorsHealthcare
- Email••••••••
- Website magnendo.com
- Social LinkedIn
- Legal Name Magnendo Corp
- Total Equity Funding$20.25M (USD)
in 2 rounds
- Latest Funding Round$18M (USD), Series A
Jul 2026
Products & Services of Magnendo
Magnendo offers a comprehensive portfolio of products and services, including Robotic Guidewire and Neurovascular Robotic System.
Enables magnetic steering for safer brain vasculature navigation in procedures.
Facilitates telerobotic interventions to treat strokes and aneurysms effectively.
Funding Insights of Magnendo
Magnendo has successfully raised a total of $20.25M across 2 strategic funding rounds. The most recent funding activity was a Series A round of $18 million completed in July 2026. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $20.25M
- Total Rounds 2
- Last Round Series A — $18M
- First Round $2.25M
(Jun 2024)
All 2 funding rounds of Magnendo with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul 2026 | $18M | Series A | – | – | – |
| Jun 2024 | $2.25M | Seed | – | – | – |
People of Magnendo
3 people are tracked at Magnendo (3 in leadership).
| Name | Role | Group |
|---|---|---|
Miki Rosenberg | Co-Founder & CDO | Leadership |
Yoonho Kim | Founder & CEO | Leadership |
Aman B Patel | CMO | Leadership |
Complete people profiles for Magnendo
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Magnendo
3 dated milestones of Magnendo across 2 years, from founding to its latest funding, stage changes and deals.
- Founded Magnendo is founded.
- Funding First funding round of $2.3M.
- Funding Latest funding round, Series A, of $18.0M.
Competitors of Magnendo
Magnendo has 2 listed competitors in our database, 2 of them funded. They include Route 92 Medical and Autonomix.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| route92medical.com | 2015 | San Mateo, United States | $167.15M | 51 | Next-generation products for neurointerventional procedures are developed. | |
| autonomix.com | 2014 | The Woodlands, United States | $8.2M | Minimally invasive neural monitoring and treatment devices are developed. |
Detailed competitors of Magnendo
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Neurology
3 companies that operate in the same segment as Magnendo (Neurology) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 | |
Developer of therapeutics for psychiatric and neurologic diseases | 2002 | New York, New York, United States | USD 80.87 M | USD 250.31 M | 600 | |
Biologics platform developed for intracellular delivery in rare diseases. | 2016 | Boston, Massachusetts, United States | USD 175.25 M | USD 25.42 M | 183 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Magnendo
Complete news archive for Magnendo
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Magnendo
Magnendo was founded in 2024.
Magnendo is headquartered in Boston, United States. It is registered at Boston, Massachusetts, United States.
Yoonho Kim is the CEO of Magnendo, as recorded in our data. They have also founded this company.
Magnendo is a funded company, having raised a total of $20.25M across 2 funding rounds to date. The company's 1st funding round was a Seed of $2.25M, raised on Jun 2024.
Magnendo was founded in 2024 in Boston, United States, within the medtech sector focused on neurovascular applications. Devices such as magnetically steerable soft-robotic guidewires are developed for minimally invasive procedures addressing stroke and brain aneurysms. Operations center on improving procedural efficiency and reducing complications in the brains vasculature, with services targeted at healthcare providers to enhance patient outcomes.
Magnendo's top competitors include Route 92 Medical and Autonomix.
Magnendo offers Robotic Guidewire and Neurovascular Robotic System.
Magnendo operates through Magnendo Corp.